6-(cyclopropylamino)-9-[2-(ethylamino)pyrimidin-4-yl]-2-(trifluoromethyl)purine | 660867-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 6-(cyclopropylamino)-9-[2-(ethylamino)pyrimidin-4-yl]-2-(trifluoromethyl)purine
• 英文别名: N-cyclopropyl-9-[2-(ethylamino)pyrimidin-4-yl]-2-(trifluoromethyl)purin-6-amine
• CAS: 660867-35-6
• 化学式: C₁₅H₁₅F₃N₈
• 分子量: 364.333
• InChiKey: JNQGTRYUQRMGJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  93.4
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• Phosphodiesterase 4 inhibitors
  申请人：Tehim Ashok

  公开号：US20070093510A1

  公开（公告）日：2007-04-26

  PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R 1 and R 2 are as defined herein.

  PDE4抑制是通过公式I的新化合物实现的：其中R1和R2如此定义。
• PHOSPHODIESTERASE 4 INHIBITORS
  申请人：Tehim Ashok

  公开号：US20100004236A1

  公开（公告）日：2010-01-07

  PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R 1 and R 2 are as defined herein.

  PDE4抑制是通过公式I中的新化合物实现的：其中R1和R2如此定义。
• DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS
  申请人：Memory Pharmaceuticals Corporation

  公开号：EP1529049B1

  公开（公告）日：2009-11-18
• US7332486B2
  申请人：——

  公开号：US7332486B2

  公开（公告）日：2008-02-19
• [EN] COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS<br/>[FR] COMBINAISONS D'INHIBITEURS DE PDE4 ET D'ANTIPSYCHOTIQUES POUR LE TRAITEMENT DE TROUBLES PSYCHOTIQUES
  申请人：MEMORY PHARM CORP

  公开号：WO2009067607A2

  公开（公告）日：2009-05-28

  The invention relates to methods and compositions for treating a psychotic disorder or condition, associated with cognitive impairment. The pharmaceutical composition comprises: (a) an amount of an antipsychotic agent and (b) an amount of a PDE4 inhibitor compound, wherein the amounts of (a) and (b) are together effective in treating the cognitive impairment or psychotic disorder such as schizophrenia. The method of treatment comprises administering to a patient (a) an amount of a antipsychotic agent and (b) an amount of a PDE4 inhibitor compound, wherein the amounts of (a) and (b) are together effective in treating the psychotic disorder such as schizophrenia.